Fractyl Health (GUTS) Competitors

$0.69 -0.03 (-4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.69 0.00 (-0.56%)

As of 06:57 PM Eastern

GUTS vs. DCTH, CLPT, CV, RXST, and TLSI

Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include Delcath Systems (DCTH), ClearPoint Neuro (CLPT), CapsoVision (CV), RxSight (RXST), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.

How does Fractyl Health compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

: In the previous week, Fractyl Health had 1 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for Fractyl Health and 2 mentions for Delcath Systems. Fractyl Health's average media sentiment score of 1.90 beat Delcath Systems' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Delcath Systems
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.
: Delcath Systems has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $85.23M 4.66 $2.70M $0.07 164.71
Fractyl Health N/A N/A -$140.95M -$1.84 N/A
: 61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 26.1% of Fractyl Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Delcath Systems presently has a consensus price target of $22.50, suggesting a potential upside of 95.14%. Fractyl Health has a consensus price target of $5.40, suggesting a potential upside of 678.21%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Delcath Systems.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Fractyl Health
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: Delcath Systems has a net margin of 3.17% compared to Fractyl Health's net margin of 0.00%. Delcath Systems' return on equity of 2.63% beat Fractyl Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Delcath Systems 3.17% 2.63% 2.39%
Fractyl Health N/A -2,896.77% -104.24%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.66	$2.70M	$0.07	164.71
Fractyl Health	N/A	N/A	-$140.95M	-$1.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	3.17%	2.63%	2.39%
Fractyl Health	N/A	-2,896.77%	-104.24%

Summary

Delcath Systems beats Fractyl Health on 10 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to ClearPoint Neuro?

Fractyl Health (NASDAQ:GUTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

: ClearPoint Neuro has higher revenue and earnings than Fractyl Health. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fractyl Health N/A N/A -$140.95M -$1.84 N/A
ClearPoint Neuro $36.97M 9.00 -$25.54M -$0.91 N/A
: 30.1% of ClearPoint Neuro shares are held by institutional investors. 26.1% of Fractyl Health shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Fractyl Health has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
: In the previous week, Fractyl Health had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for Fractyl Health and 1 mentions for ClearPoint Neuro. Fractyl Health's average media sentiment score of 1.90 beat ClearPoint Neuro's score of 0.36 indicating that Fractyl Health is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
ClearPoint Neuro
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Fractyl Health currently has a consensus price target of $5.40, suggesting a potential upside of 678.21%. ClearPoint Neuro has a consensus price target of $14.50, suggesting a potential upside of 30.63%. Given Fractyl Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Fractyl Health is more favorable than ClearPoint Neuro.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
ClearPoint Neuro
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Fractyl Health has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -69.08%. ClearPoint Neuro's return on equity of -122.17% beat Fractyl Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Fractyl Health N/A -2,896.77% -104.24%
ClearPoint Neuro -69.08% -122.17% -40.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$1.84	N/A
ClearPoint Neuro	$36.97M	9.00	-$25.54M	-$0.91	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-2,896.77%	-104.24%
ClearPoint Neuro	-69.08%	-122.17%	-40.69%

Summary

Fractyl Health beats ClearPoint Neuro on 9 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to CapsoVision?

Fractyl Health (NASDAQ:GUTS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

: CapsoVision has higher revenue and earnings than Fractyl Health. CapsoVision is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fractyl Health N/A N/A -$140.95M -$1.84 N/A
CapsoVision $13.55M 25.97 -$25.32M -$2.19 N/A
: In the previous week, Fractyl Health had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Fractyl Health and 2 mentions for CapsoVision. Fractyl Health's average media sentiment score of 1.90 beat CapsoVision's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Fractyl Health currently has a consensus price target of $5.40, suggesting a potential upside of 678.21%. CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 20.40%. Given Fractyl Health's higher possible upside, equities research analysts clearly believe Fractyl Health is more favorable than CapsoVision.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
CapsoVision
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
: CapsoVision's return on equity of 0.00% beat Fractyl Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Fractyl Health N/A -2,896.77% -104.24%
CapsoVision N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$1.84	N/A
CapsoVision	$13.55M	25.97	-$25.32M	-$2.19	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-2,896.77%	-104.24%
CapsoVision	N/A	N/A	N/A

Summary

Fractyl Health and CapsoVision tied by winning 6 of the 12 factors compared between the two stocks.

How does Fractyl Health compare to RxSight?

RxSight (NASDAQ:RXST) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

: RxSight has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Fractyl Health has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.
: 78.8% of RxSight shares are owned by institutional investors. 9.6% of RxSight shares are owned by insiders. Comparatively, 26.1% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, RxSight and RxSight both had 3 articles in the media. Fractyl Health's average media sentiment score of 1.90 beat RxSight's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Fractyl Health has a net margin of 0.00% compared to RxSight's net margin of -28.96%. RxSight's return on equity of -14.05% beat Fractyl Health's return on equity.
Company Net Margins Return on Equity Return on Assets
RxSight -28.96% -14.05% -12.54%
Fractyl Health N/A -2,896.77% -104.24%
: RxSight has higher revenue and earnings than Fractyl Health. RxSight is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
Fractyl Health N/A N/A -$140.95M -$1.84 N/A
: RxSight presently has a consensus price target of $9.78, indicating a potential upside of 34.68%. Fractyl Health has a consensus price target of $5.40, indicating a potential upside of 678.21%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts clearly believe Fractyl Health is more favorable than RxSight.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
Fractyl Health
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-28.96%	-14.05%	-12.54%
Fractyl Health	N/A	-2,896.77%	-104.24%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$1.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Fractyl Health beats RxSight on 8 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to TriSalus Life Sciences?

Fractyl Health (NASDAQ:GUTS) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

: Fractyl Health has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
: 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 26.1% of Fractyl Health shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Fractyl Health presently has a consensus price target of $5.40, indicating a potential upside of 678.21%. TriSalus Life Sciences has a consensus price target of $7.00, indicating a potential upside of 51.84%. Given Fractyl Health's stronger consensus rating and higher possible upside, research analysts plainly believe Fractyl Health is more favorable than TriSalus Life Sciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
TriSalus Life Sciences
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Fractyl Health and Fractyl Health both had 3 articles in the media. Fractyl Health's average media sentiment score of 1.90 beat TriSalus Life Sciences' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fractyl Health
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
TriSalus Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: TriSalus Life Sciences has higher revenue and earnings than Fractyl Health. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fractyl Health N/A N/A -$140.95M -$1.84 N/A
TriSalus Life Sciences $45.15M 6.26 -$39.23M -$1.83 N/A
: Fractyl Health has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -86.88%. TriSalus Life Sciences' return on equity of 0.00% beat Fractyl Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Fractyl Health N/A -2,896.77% -104.24%
TriSalus Life Sciences -86.88% N/A -94.43%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$1.84	N/A
TriSalus Life Sciences	$45.15M	6.26	-$39.23M	-$1.83	N/A

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-2,896.77%	-104.24%
TriSalus Life Sciences	-86.88%	N/A	-94.43%

Summary

Fractyl Health beats TriSalus Life Sciences on 8 of the 14 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$110.09M	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-0.38	18.37	29.04	28.47
Price / Sales	N/A	281.31	476.61	60.94
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	9.91	4.33	9.67	6.67
Net Income	-$140.95M	$72.19M	$3.55B	$332.53M
7 Day Performance	5.73%	2.02%	1.70%	2.01%
1 Month Performance	52.20%	6.41%	5.62%	9.20%
1 Year Performance	-57.43%	37.73%	34.42%	39.59%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	3.7011 of 5 stars	$0.69 -4.6%	$5.40 +678.2%	N/A	$110.09M	N/A	N/A	102	News Coverage Positive News Upcoming Earnings
DCTH Delcath Systems	1.6232 of 5 stars	$10.84 flat	$22.50 +107.6%	N/A	$373.49M	$85.23M	154.86	60	Upcoming Earnings
CLPT ClearPoint Neuro	1.7968 of 5 stars	$11.21 -4.8%	$14.50 +29.3%	N/A	$353.23M	$36.97M	N/A	110	Upcoming Earnings
CV CapsoVision	1.5593 of 5 stars	$6.37 +4.9%	$8.50 +33.4%	N/A	$302.52M	$13.55M	N/A	90	News Coverage
RXST RxSight	1.5643 of 5 stars	$7.29 +0.6%	$9.78 +34.1%	N/A	$299.18M	$134.48M	N/A	220	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. DCTH, CLPT, CV, RXST, and TLSI

How does Fractyl Health compare to Delcath Systems?

Summary

How does Fractyl Health compare to ClearPoint Neuro?

Summary

How does Fractyl Health compare to CapsoVision?

Summary

How does Fractyl Health compare to RxSight?

Summary

How does Fractyl Health compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. DCTH, CLPT, CV, RXST, and TLSI

How does Fractyl Health compare to Delcath Systems?

Summary

How does Fractyl Health compare to ClearPoint Neuro?

Summary

How does Fractyl Health compare to CapsoVision?

Summary

How does Fractyl Health compare to RxSight?

Summary

How does Fractyl Health compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools